Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum is a unicellular protozoan parasite and the most lethal species of Plasmodium that infects humans, causing the most severe form of malaria known as falciparum malaria. It is transmitted to humans through the bite of an infected female Anopheles mosquito. It's the causative agent of nearly all fatal cases of malaria. While not a direct molecular target itself, it is the organism that drugs target, and its proteins and pathways are the actual drug targets (e.g., PfNCR1).
Varies depending on the specific drug; examples include inhibition of parasite enzymes (e.g., dihydrofolate reductase), disruption of heme polymerization, and interference with electron transport.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum (P. falciparum).